Neumora Therapeutics Inc (NASDAQ:NMRA) has a beta value of 2.64 and has seen 5.28 million shares traded in the last trading session. The company, currently valued at $208.65M, closed the last trade at $1.29 per share which meant it gained $0.23 on the day or 21.70% during that session. The NMRA stock price is -1232.56% off its 52-week high price of $17.19 and 52.71% above the 52-week low of $0.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.62 million shares traded. The 3-month trading volume is 1.10 million shares.
The consensus among analysts is that Neumora Therapeutics Inc (NMRA) is Buy stock at the moment, with a recommendation rating of 2.14. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Sporting 21.70% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NMRA stock price touched $1.29 or saw a rise of 8.51%. Year-to-date, Neumora Therapeutics Inc shares have moved -87.49%, while the 5-day performance has seen it change 57.01%. Over the past 30 days, the shares of Neumora Therapeutics Inc (NASDAQ:NMRA) have changed 26.47%. Short interest in the company has seen 14.54 million shares shorted with days to cover at 15.45.
Wall Street analysts have a consensus price target for the stock at $2, which means that the shares’ value could jump 35.5% from current levels. The projected low price target is $2.0 while the price target rests at a high of $2.0. In that case, then, we find that the current price level is -55.04% off the targeted high while a plunge would see the stock gain -55.04% from current levels.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
The company’s shares have lost -50.00% over the past 6 months.
Earnings growth for 2025 is a modest 9.06% while over the next 5 years, the company’s earnings are expected to increase by 13.15%.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders own 27.57% of the company shares, while shares held by institutions stand at 60.19% with a share float percentage of 83.10%. Investors are also buoyed by the number of investors in a company, with Neumora Therapeutics Inc having a total of 156.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 8.62 million shares worth more than $84.76 million. As of 2024-06-30, FMR LLC held 5.4235% of shares outstanding.
The other major institutional holder is SOFTBANK GROUP CORP., with the holding of over 7.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $75.17 million and represent 4.8099% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 1.44% shares in the company for having 2.32 shares of worth $2.99 million while later fund manager owns 2.08 shares of worth $2.69 million as of May 31, 2025 , which makes it owner of about 1.29% of company’s outstanding stock.
